Abstract
Objective: This study aimed to assess the response of combretastatin-A4-phosphate (CA4P) in rabbit VX2 liver tumors using intravoxel incoherent motion diffusion-weighted MRI (IVIM DW-MRI).
Methods: Forty rabbits with implanted VX2 liver tumors underwent baseline MRI and were then given 10 mg/kg CA4P (n=20) or saline (n=20). After 4 h, 10 rabbits from each group underwent an MRI examination and were then sacrificed. The remaining rabbits underwent MRI after 1, 3, and 7 days and were then sacrificed. Liver samples were processed for H&E and immunohistochemical staining. IVIM parameters (D, f, D*) were compared in the treatment and control groups, and the correlations of IVIM parameters with microvascular density (MVD) were determined.
Results: At 4 h, the two treatment groups had significantly different f and D* values (p<0.001), and these values were at their minimum in the treatment group. The treatment group had moderate correlations between MVD and f at 4 h (r=0.676, p=0.032) and 7 days (r=0.656, p=0.039) and with D* at 4 h (r=0.732, p=0.016) and 7 days (r=0.748, p=0.013), but no correlation was reported between MVD and f or D* in the control group (all P>0.05).
Conclusion: IVIM DW-MRI is a sensitive imaging technique. It successfully evaluated the effect of CA4P on VX2 liver tumors in rabbits. The f and D* values correlated with MVD at 4 h and 7 days after using CA4P, indicating that these parameters have the potential to be used as indicators of tumor angiogenesis after treatment.
Keywords: Rabbits, Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging (IVIM-DW-MRI), Liver neoplasms, Vascular disrupting agent (VDA), Microvascular density (MVD), VX2 tumor.
[http://dx.doi.org/10.1159/000505814] [PMID: 31914438]
[http://dx.doi.org/10.1148/rg.2021200202] [PMID: 34270355]
[http://dx.doi.org/10.1016/j.mri.2015.10.013] [PMID: 26518059]
[http://dx.doi.org/10.1016/j.mri.2014.05.011] [PMID: 24970024]
[http://dx.doi.org/10.1016/j.neo.2017.07.010] [PMID: 28987998]
[http://dx.doi.org/10.3390/diagnostics11091684] [PMID: 34574025]
[http://dx.doi.org/10.1148/radiology.168.2.3393671] [PMID: 3393671]
[http://dx.doi.org/10.1002/mrm.24810] [PMID: 23798038]
[http://dx.doi.org/10.3390/jpm12040638] [PMID: 35455755]
[http://dx.doi.org/10.1148/radiol.14131165] [PMID: 24697148]
[http://dx.doi.org/10.1002/jmri.25075] [PMID: 26540374]
[http://dx.doi.org/10.1016/j.lungcan.2020.03.013] [PMID: 32203770]
[http://dx.doi.org/10.2147/OTT.S109186] [PMID: 27942221]
[http://dx.doi.org/10.1093/annonc/mdq708] [PMID: 21273348]
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2499]
[http://dx.doi.org/10.3748/wjg.v23.i11.1990] [PMID: 28373765]
[http://dx.doi.org/10.1002/ijc.31567] [PMID: 29707770]
[http://dx.doi.org/10.1016/j.tranon.2019.09.010] [PMID: 31810003]
[http://dx.doi.org/10.1371/journal.pone.0082649] [PMID: 24376560]
[http://dx.doi.org/10.1016/j.ejrad.2011.03.009] [PMID: 21454029]
[http://dx.doi.org/10.1007/BF00666038] [PMID: 8534865]
[http://dx.doi.org/10.1148/radiol.2372041638]
[http://dx.doi.org/10.1148/radiology.161.2.3763909] [PMID: 3763909]
[http://dx.doi.org/10.1002/jmri.26845] [PMID: 31245888]
[http://dx.doi.org/10.1016/j.ejrad.2019.108686] [PMID: 31586850]
[http://dx.doi.org/10.1016/j.oraloncology.2017.03.016] [PMID: 28438298]
[http://dx.doi.org/10.1016/j.ejrad.2018.12.005] [PMID: 30599868]
[http://dx.doi.org/10.2147/OTT.S113909] [PMID: 27799790]
[http://dx.doi.org/10.3892/ijo.21.4.717] [PMID: 12239609]
[http://dx.doi.org/10.1111/j.1365-2613.2009.00651.x] [PMID: 19563611]
[http://dx.doi.org/10.1097/CAD.0b013e328349dd60] [PMID: 21857503]
[http://dx.doi.org/10.1016/j.neuroimage.2017.12.062] [PMID: 29277647]
[http://dx.doi.org/10.1177/0284185119855731]
[http://dx.doi.org/10.1002/jmri.26885] [PMID: 31373117]
[http://dx.doi.org/10.1517/13543784.2013.759557] [PMID: 23316880]